Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: Rituximab: This group will recieve Injection Rituximab 375 mg/m2 BSA intravenous single dose as an Induction agent in Living Donor Renal Transplantation administered 7 to 21 days befor
Sponsors
Muljibhai Patel Society for reasearch in Nephro Urology
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adult patients over 18 years receiving their first ABO compatible living donor renal transplant 2.Negative CDC less than 10 percentage of flow crossmatch 3.Negative baseline DSA with MFI less than 1000 by Luminex SAB assay Written informed consent.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess graft and patient outcome after single dose Rituximab induction after 1 year in ABO compatible and DSA negative kidney transplant patientsTimepoint: To assess Anti DSA titers at baseline and after 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Biopsy proven acute rejection (Banff classification) 2.Renal function- Serum creatinine and eGFR at 1, 3, 6, 9, 12 months. 3.Infections: BK viremia, CMV viremia, opportunistic infections 4.Adverse Events of Special Interest: Infusion reactions, neutropenia,lymphopenia, hypogammaglobulinemia 5.Hospitalizations and readmissions within 12 months. Timepoint: At 12 months | — |
Countries
India
Contacts
Public ContactDrSishir Gang
Muljibhai Patel Urological Hospital, Nadiad
Outcome results
None listed